Humacyte Statistics

Total Valuation

Humacyte has a market cap or net worth of $475.15 million. The enterprise value is $441.49 million.

Market Cap	475.15M
Enterprise Value	441.49M

Important Dates

The next estimated earnings date is Friday, May 10, 2024, before market open.

Earnings Date	May 10, 2024
Ex-Dividend Date	n/a

Share Statistics

Humacyte has 119.08 million shares outstanding. The number of shares has increased by 0.36% in one year.

Shares Outstanding	119.08M
Shares Change (YoY)	+0.36%
Shares Change (QoQ)	+0.16%
Owned by Insiders (%)	31.42%
Owned by Institutions (%)	15.29%
Float	81.64M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	34.29
P/FCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 4.52, with a Debt / Equity ratio of 4.25.

Current Ratio	4.52
Quick Ratio	n/a
Debt / Equity	4.25
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-15.79

Financial Efficiency

Return on equity (ROE) is -228.90% and return on invested capital (ROIC) is -140.81%.

Return on Equity (ROE)	-228.90%
Return on Assets (ROA)	-70.50%
Return on Capital (ROIC)	-140.81%
Revenue Per Employee	n/a
Profits Per Employee	-$605,333
Employee Count	183
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +16.87% in the last 52 weeks. The beta is 1.45, so Humacyte's price volatility has been higher than the market average.

Beta (1Y)	1.45
52-Week Price Change	+16.87%
50-Day Moving Average	3.53
200-Day Moving Average	3.11
Relative Strength Index (RSI)	65.21
Average Volume (30 Days)	1,349,495

Short Selling Information

The latest short interest is 3.94 million, so 3.31% of the outstanding shares have been sold short.

Short Interest	3.94M
Short Previous Month	3.98M
Short % of Shares Out	3.31%
Short % of Float	4.83%
Short Ratio (days to cover)	3.54

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-100.05M
Pretax Income	-110.78M
Net Income	-110.78M
EBITDA	-96.41M
EBIT	-104.18M
Earnings Per Share (EPS)	-$1.07

Full Income Statement

Balance Sheet

The company has $80.45 million in cash and $57.51 million in debt, giving a net cash position of $22.94 million or $0.19 per share.

Cash & Cash Equivalents	80.45M
Total Debt	57.51M
Net Cash	22.94M
Net Cash Per Share	$0.19
Equity / Book Value	13.55M
Book Value Per Share	0.11
Working Capital	64.84M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$73.31 million and capital expenditures -$2.28 million, giving a free cash flow of -$75.59 million.

Operating Cash Flow	-73.31M
Capital Expenditures	-2.28M
Free Cash Flow	-75.59M
FCF Per Share	-$0.73

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Humacyte does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-0.36%
Shareholder Yield	-0.36%
Earnings Yield	-23.85%
FCF Yield	-16.27%

Analyst Forecast

The average price target for Humacyte is $7.00, which is 75.44% higher than the current price. The consensus rating is "Buy".

Price Target	$7.00
Price Target Difference	75.44%
Analyst Consensus	Buy
Analyst Count	5
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	1